Matters of legal in nature including licensing, intellectual property, and lawsuits.
RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 10, 2020– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its President and CEO, Patrick Decker, and Vice President of Investor Relations, Matt Latino, will participate in a virtual fireside chat hosted by RBC analyst Deane Dray... Read more
Phase III clinical trial programme initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) Phase IIIb clinical trial programme of higher-dose OCREVUS (ocrelizumab) to evaluate impact on reducing disability progression in RMS and PPMS OCREVUS CHIMES... Read more
New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations Initiation of Phase III clinical trial programme for fenebrutinib, an investigational... Read more
08/28/2020 | Press Release Towards the Commercialization of Analytical and Measuring Instruments that Combine a High-Performance Liquid Chromatograph and a Raman Spectrometer On August 3rd, Shimadzu Corporation (President & CEO: Teruhisa Ueda, hereinafter Shimadzu) and HORIBA, Ltd. (President & COO: Masayuki Adachi, hereinafter HORIBA) concluded a basic agreement to commence collaboration on the development and sales of... Read more
CHELMSFORD, Mass., Aug. 27, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in Citi’s 2020 Global Technology Virtual Conference on Wednesday, September 9, 2020 which includes a 45-minute webcast beginning at 9:50 a.m. ET. The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/events. A replay... Read more
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System Demonstrated 100 Percent Agreement with Authorized Nasopharyngeal Assays SOUTH SAN FRANCISCO, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight,... Read more
IRVINE, Calif., (Aug. 19, 2020) — Zymo Research announced that it was recently granted the CE IVD Mark for its Quick SARS-CoV-2 rRT-PCR Kit. To obtain this certification the product had to comply with the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. The Quick SARS-CoV-2 rRT-PCR Kit is... Read more
Basel, 10 August 2020 In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants survive without permanent ventilation and achieve the ability to sit without support, a key motor milestone not... Read more
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival (PFS) for the initial (first-line) treatment of people with metastatic... Read more
HERCULES, Calif. –Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the The United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld... Read more